Home Cart Sign in  
Chemical Structure| 99896-85-2 Chemical Structure| 99896-85-2
Chemical Structure| 99896-85-2

RGD

CAS No.: 99896-85-2

Arg-Gly-Asp is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.

Synonyms: Arg-Gly-Asp; RGD Peptides

4.5 *For Research Use Only !

Cat. No.: A518854 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
100mg łÇǧ¶ÊÊ Inquiry Inquiry
250mg łÇóͶÊÊ Inquiry Inquiry
1g łÍî§¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 100mg

    łÇǧ¶ÊÊ

  • 250mg

    łÇóͶÊÊ

  • 1g

    łÍî§¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of RGD

CAS No. :99896-85-2
Formula : C12H22N6O6
M.W : 346.34
SMILES Code : O=C(NCC(N[C@@H](CC(O)=O)C(O)=O)=O)[C@H](CCCNC(N)=N)N
Synonyms :
Arg-Gly-Asp; RGD Peptides
MDL No. :MFCD00057952
InChI Key :IYMAXBFPHPZYIK-BQBZGAKWSA-N
Pubchem ID :104802

Safety of RGD

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of RGD

cytoskeleton

Isoform Comparison

Biological Activity

Target
  • Integrin

In Vitro:

Cell Line
Concentration Treated Time Description Reference
Bone Marrow-Derived Macrophages (BMDMs) 100,000 cells/cm² 24 hours To evaluate the effect of dynamic RGD pattern on macrophage morphology and phenotype, results showed that after UV irradiation, macrophages transformed from round to elongated morphology and switched from pro-inflammatory to anti-inflammatory phenotype. PMC8089772
MDA-MB-231 cells 0.3 nM or 1 nM 48 hours To evaluate the inhibitory effect of RGD/P-AuNPs on the invasive activity of breast cancer cells, the results showed that RGD/P-AuNPs significantly inhibited radiation-induced invasive activity. PMC5560413
Hs578T cells 0.3 nM or 1 nM 48 hours To evaluate the inhibitory effect of RGD/P-AuNPs on the invasive activity of breast cancer cells, the results showed that RGD/P-AuNPs significantly inhibited radiation-induced invasive activity. PMC5560413

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01806675 Adult Giant Cell Glioblastoma ... More >> Adult Glioblastoma Adult Gliosarcoma Male Breast Cancer Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Adult Brain Tumor Recurrent Basal Cell Carcinoma of the Lip Recurrent Breast Cancer Recurrent Colon Cancer Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Recurrent Hypopharyngeal Cancer Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Recurrent Laryngeal Cancer Recurrent Lip and Oral Cavity Cancer Recurrent Lymphoepithelioma of the Nasopharynx Recurrent Lymphoepithelioma of the Oropharynx Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Recurrent Mucoepidermoid Carcinoma of the Oral Cavity Recurrent Nasopharyngeal Cancer Recurrent Non-small Cell Lung Cancer Recurrent Oropharyngeal Cancer Recurrent Pancreatic Cancer Recurrent Paranasal Sinus and Nasal Cavity Cancer Recurrent Rectal Cancer Recurrent Renal Cell Cancer Recurrent Salivary Gland Cancer Stage IIIA Breast Cancer Stage IIIA Non-small Cell Lung Cancer Stage IIIB Breast Cancer Stage IIIB Non-small Cell Lung Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Stage IV Non-small Cell Lung Cancer Stage IV Pancreatic Cancer Stage IV Renal Cell Cancer Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVA Salivary Gland Cancer Stage IVB Colon Cancer Stage IVB Salivary Gland Cancer Stage IVC Salivary Gland Cancer Tongue Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Phase 2 Active, not recruiting March 2019 United States, California ... More >> Stanford University, School of Medicine Stanford, California, United States, 94305 Less <<
NCT01492192 Carcinoma, Renal Cell Phase 2 Terminated - United Kingdom ... More >> Department of Radiology, Oxford University Hospitals NHS Trust Oxford, Oxfordshire, United Kingdom, OX3 7LJ Less <<
NCT02995642 Aortic Aneurysm, Abdominal ... More >> Carotid Atherosclerosis Less << Phase 2 Not yet recruiting December 2019 United States, California ... More >> Stanford University Not yet recruiting Stanford, California, United States, 94305 Contact: Andrea Otte    650-736-4183    anotte@stanford.edu    Contact: Lacey Greene, MS, CNMT    6507254712    lacey.greene@stanford.edu    Principal Investigator: Guido Davidzon, MD          Sub-Investigator: Andrei Iagaru, MD Less <<
NCT00565721 High-grade Glioma ... More >> Lung Cancer Head & Neck Cancer Sarcoma Melanoma Less << Phase 2 Completed - United States, New Jersey ... More >> GE Healthcare Office Princeton, New Jersey, United States, 08540 Less <<
NCT00565721 - Completed - -
NCT01176500 Colon Cancer ... More >>Lung Cancer Cervical Cancer Renal Cell Carcinoma Uterine Cancer Less << Phase 1 Phase 2 Withdrawn - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00364728 - Unknown July 2012 Taiwan ... More >> Chung-Yi Hu Recruiting Taipei, Taiwan, Taiwan, 100 Contact: Chung-Yi Hu, PhD    886-2-23123456 ext 66914    jcyhu@ntu.edu.tw    Contact: Ping-Ning Hsu, PhD    886-2-23123456 ext 88635    phsu8635@ntu.edu.tw    Principal Investigator: Chung-Yi Hu, PhD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.89mL

0.58mL

0.29mL

14.44mL

2.89mL

1.44mL

28.87mL

5.77mL

2.89mL

References

 

Historical Records

Categories